CoChat
Sign Up
Cited by 170Potassium and Related DisordersHeart Failure Treatment and ManagementHormonal Regulation and Hypertension

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Incidence and Predictors of Hyperkalemia in Patients With Heart Failure

Open access
Desai, Akshay S., Swedberg, Karl, McMurray, John J.V., Granger, Christopher B., Yusuf, Salim, Young, James B., Dunlap, Mark E., Solomon, Scott D., Hainer, James W., Olofsson, Bertil, Michelson, Eric L., Pfeffer, Marc A.·2007·Journal of the American College of Cardiology
DOI 10.1016/j.jacc.2007.07.067
Open this paper in CoChat — free account

Abstract

Objectives We explored the incidence and predictors of hyperkalemia in a broad population of heart failure patients.Background When used in optimal doses to treat patients with heart failure, renin-angiotensin-aldosterone system (RAAS) inhibitors improve clinical outcomes but can cause hyperkalemia.Methods Participants in the CHARM (Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity) (n = 7,599) Program were randomized to standard heart failure therapy plus candesartan or placebo, titrated as tolerated to a target of 32 mg once daily with recommended monitoring of serum potassium and creatinine. We assessed the incidence and predictors of hyperkalemia associated with dose reduction, study drug discontinuation, hospitalization, or death over the median 3.2 years of follow-up.Results Independent of treatment assignment, the risk of hyperkalemia increased with age > or =75 years, male gender, diabetes, creatinine > or =2.0 mg/dl, K+ > or =5.0 mmol/l, and background use of angiotensin-converting enzyme inhibitors or spironolactone. Candesartan increased the rate of aggregate hyperkalemia from 1.8% to 5.2% (difference 3.4%, p < 0.0001) and serious hyperkalemia (associated with death or hospitalization) from 1.1% to 1.8% (difference 0.7%, p < 0.001), with hyperkalemia associated with death reported in 2 (0.05%) candesartan patients and 1 (0.03%) placebo patient. The benefit of candesartan in reducing cardiovascular death or heart failure hospitalization (relative risk reduction 16%, p < 0.0001) was uniform in these subgroups, as was the incremental risk of hyperkalemia.Conclusions The risk of hyperkalemia is increased in symptomatic heart failure patients with advanced age, male gender, baseline hyperkalemia, renal failure, diabetes, or combined RAAS blockade. Although these groups derive incremental clinical benefit from candesartan, careful surveillance of serum potassium and creatinine is particularly important.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2007.07.067

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 21 references

Cited by

Sorted by citations

Items 101–170 of 170

Related

See all

Metadata

Authors
Desai, A. S., Swedberg, K., McMurray, J. J. V., Granger, C. B., Yusuf, S., Young, J. B., Dunlap, M. E., Solomon, S. D., Hainer, J. W., Olofsson, B., Michelson, E. L., & Pfeffer, M. A.
Affiliations
  • Brigham and Women's Hospital (US)
  • University of Gothenburg (SE)
  • Western Infirmary (GB)
  • Duke Medical Center (US)
  • Cleveland Clinic (US)
  • Case Western Reserve University (US)
  • AstraZeneca (United States) (US)
ORCID
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2007-11
Volume
50
Issue
20
Pages
1959-1966
ISSN
0735-1097 (ISSN-L)
DOI
10.1016/j.jacc.2007.07.067
OpenAlex
W170303893
Cited by
170
References
21
Citations by year
2026: 1 · 2025: 9 · 2024: 9 · 2023: 5 · 2022: 5 · 2021: 11 · 2020: 2 · 2019: 13 · 2018: 14 · 2017: 13 · 2016: 8 · 2015: 4 · 2014: 9 · 2013: 9 · 2012: 15
FWCI
8.35
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Nephrology › Potassium and Related Disorders
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
Keywords
hyperkalemia, heart failure, candesartan, renin-angiotensin-aldosterone system inhibitors, risk factors, serum potassium monitoring, renal failure, diabetes mellitus, spironolactone, ACE inhibitors, drug safety, cardiovascular mortality
MeSH terms
Aged, Aged, 80 and over, Benzimidazoles, Biphenyl Compounds, Female, Follow-Up Studies, Heart Failure, Humans, Hyperkalemia, Male, Predictive Value of Tests, Retrospective Studies, Risk Factors, Tetrazoles, Incidence, Angiotensin II Type 1 Receptor Blockers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review